The 29th Napa Pain Conference

Call for Abstracts


The deadline for abstract submissions has passed, and results are currently being sent.

The Program Committee invites you to submit abstracts for papers and ePosters to be presented at the 29th Napa Pain Conference.

Share your research, clinical outcomes, quality improvement initiatives, practice improvements, or patient care strategies at one of the nation’s most unique pain conferences.

Download the Abstract Guide


Extended Deadline: Friday, July 15, 2022, by 11:59 PM PST


Neurovations Partners with Frontiers in Pain Research to Bring Publishing to the Forefront

Neurovations Education and the Napa Pain Conference (NPC) have partnered with the journal Frontiers in Pain Research to create a publishing opportunity for research in pain intervention. The partnership will ensure abstract publication from the Napa Pain Conference and will forge a pathway for the publication of new pain research articles.

Dr. Tony Yaksh, the Editor in Chief of the journal Frontiers in Pain Research believes this partnership can open new opportunities and facilitate advances in pain research and management by enhancing knowledge dissemination.

“All quality studies contributing insights to the pathophysiology of pain and development of novel analgesics for improved clinical treatment and patient quality of life are welcome in this journal,” stated Dr. Yaksh.

The scope of the journal, as is the field of pain research, is dauntingly expansive, but reflects a threefold focus for the manuscripts submission:
i) Elucidation of pain biology
ii) Characterization of pain interventions
iii) Clinical Translation

Learn more...


  • Abstract Submission: Now - July 15, 2022, by 11:59 pm PDT
  • Results: July 20, 2022
  • ePosters Due: July 21 - 28, 2022
  • ePosters Posted: August 1, 2022
  • Napa Pain Conference: August 18 - 21, 2022

The Program Committee is accepting original abstracts in the following categories. If your work doesn’t fit within an established category, please submit it under “Miscellaneous”. If necessary, include a second category to ensure that your abstract is sent to the optimal combination of reviewers relevant to the content of your abstract. Not every abstract fits neatly into a single category and the identification of a secondary category might be helpful during the review and program construction process.

  • Abdominal and Pelvic Pain
  • Cancer Pain
  • Cannabis (medical use of)/Cannabinoids
  • Clinical advancements in pain management
  • Clinical Trials, Methods, and Evidence Synthesis
  • COVID-19 / PASC related pain
  • Geriatric Pain
  • Interventional pain management techniques
  • Migraine/Headache
  • Musculoskeletal Pain
  • Neuromodulatory Interventions
  • Neuropathic Pain
  • Neuroscience, Neuroimaging & Neuroanatomy
  • Non-Pharmacological Treatment of Pain
  • Opioid use disorder and overdose treatment, including buprenorphine and naloxone
  • Pain Mechanisms
  • Pain Research Methods
  • Patient communications, including adherence to treatment plans
  • Pediatric Pain
  • Pharmacological Treatment of Pain
  • Practice management, including implementation of EHR and transitioning to ICD-10
  • Quality Improvement (QI) initiatives undertaken at your institution that improved clinical care, service, cost or patient outcomes
  • Regenerative medicine
  • Targeted drug delivery/Intrathecal drug delivery
  • Veterinary and Comparative Pain
  • Miscellaneous

Considerations for All Abstracts

There is no limit to the number of abstracts an author may submit for consideration. However, multiple submissions of the same or nearly the same abstract by the same author(s)/institution(s) is grounds for rejection of all submitted abstracts from the submitting parties.

Abstracts submitted to, or presented at, other societies or national meetings may only be submitted for consideration if:

  • The prior submission is not currently under review by the other organization;
  • You have retained copyright authority vs. transferring copyright to the previous entity; and
  • You disclose prior publication as part of the abstract, as this must be considered in scoring abstracts.

All recommendations involving clinical medicine must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients.

All submissions must be HIPAA-compliant. Patient confidentiality must be protected. No names, hospital ID numbers, or any other identifying information can appear in your work.

All scientific research referred to, reported, or used in support or justification of a patient care recommendation must conform to generally accepted standards of experimental design, data collection, and analysis.

Employees and owners of companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients are encouraged to submit “poster-only” abstracts. Posters are not part of the CME-certified content and are a great way to convey the latest research and developments.

A presenter is not to receive financial support in conjunction with their presentation(s), except from their employer.

In submitting an abstract, all authors retain copyright to the content and agree to grant Neurovations Education a limited, nonexclusive, royalty-free license to present, reproduce, or create derivative works of the content online, in print, and in other media or publications associated with its educational programs, and to archive and distribute the content online and in other means.

Reviewer scores and comments are confidential and will not be made available to anyone (including authors) outside of the immediate review process.

Bias in favor of a particular product or company is grounds for rejection. Use of a particular company’s products or equipment in itself does not represent bias. Likewise, research involving a single method, drug, or device would not constitute bias if it conforms to best practices of study design and analysis. Non-data-driven statements of superiority, however, would be considered biased.

A presenting author must be registered for the 29th Napa Pain Conference prior to the submission deadline for the abstract to be considered.

By virtue of submitting the abstract, the submitting author verifies that all authors agree:

  • to the submission of the abstract to the 29th Napa Pain Conference
  • that the abstract constitutes an original work
  • that copyright permissions have been secured (as necessary) for included material
  • the abstract includes valid, accurate, and balanced content
  • to grant Neurovations Education (Neurovations) and other entities – e.g. contractors or broadcasters – as Neurovations may designate, the right to reproduce, stream, distribute, display, and provide the abstract, in whole or in part, as well as accompanying works including but not limited to associated posters, in any and all media or form of communication whether now existing or hereafter developed. Authors also grant Neurovations and its agents the right to transcribe, publish, edit, distribute, sell or otherwise disseminate the works, in part or in whole, alone or as part of a compilation, and/or make derivatives works of it at Neurovations’ discretion without additional approval from authors, in whole or in part, throughout the world, in perpetuity, in any and all media now known or hereafter developed.

Submission of an abstract constitutes a commitment by the author(s) to present their work, if accepted.

Expenses associated with the production and presentation of an abstract are the responsibility of the presenter. This includes, but is not limited to, the production of posters, registration for the Conference, and any associated travel.

A presenting author of each abstract must register for the 29th Napa Pain Conference. Submission of an abstract does not automatically register you for the conference.

If selected, your Poster is expected to reflect the contents of your abstract. Substantial deviation from the published abstract or failure to present may jeopardize acceptance for future abstracts.

Nothing in this authorization constitutes an affirmative obligation on the part of Neurovations to use the abstract or accompanying works in any way.

Embargo & Release

Conference abstracts, ePosters, and ePresentations will be published on August 1, 2022. Once the abstract has been published, the embargo has lifted.

Special arrangements may be available for early or late publication through coordination with Neurovations Education (Education@Neurovations.com), however alternate dates of publication are not guaranteed.



Email the team at Neurovations Education with any questions.